- Home
- CGEN vs OBIO Comparison
CGEN vs OBIO Comparison
Compare CGEN & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- OBIO
- Stock Information
- Founded
- CGEN 1993
- OBIO 2017
- Country
- CGEN Israel
- OBIO United States
- Employees
- CGEN N/A
- OBIO N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- CGEN Health Care
- OBIO Health Care
- Exchange
- CGEN Nasdaq
- OBIO Nasdaq
- Market Cap
- CGEN 125.3M
- OBIO 146.2M
- IPO Year
- CGEN 2000
- OBIO N/A
- Fundamental
- Price
- CGEN $1.75
- OBIO $2.70
- Analyst Decision
- CGEN
- OBIO Strong Buy
- Analyst Count
- CGEN 0
- OBIO 4
- Target Price
- CGEN N/A
- OBIO $14.00
- AVG Volume (30 Days)
- CGEN 377.9K
- OBIO 222.4K
- Earning Date
- CGEN 11-11-2025
- OBIO 11-11-2025
- Dividend Yield
- CGEN N/A
- OBIO N/A
- EPS Growth
- CGEN N/A
- OBIO N/A
- EPS
- CGEN N/A
- OBIO N/A
- Revenue
- CGEN $22,144,000.00
- OBIO $2,944,000.00
- Revenue This Year
- CGEN N/A
- OBIO $29.26
- Revenue Next Year
- CGEN $208.08
- OBIO $10.65
- P/E Ratio
- CGEN N/A
- OBIO N/A
- Revenue Growth
- CGEN N/A
- OBIO 41.61
- 52 Week Low
- CGEN $1.13
- OBIO $2.20
- 52 Week High
- CGEN $2.66
- OBIO $6.50
- Technical
- Relative Strength Index (RSI)
- CGEN 66.91
- OBIO 55.64
- Support Level
- CGEN $1.30
- OBIO $2.20
- Resistance Level
- CGEN $1.82
- OBIO $2.89
- Average True Range (ATR)
- CGEN 0.11
- OBIO 0.14
- MACD
- CGEN 0.05
- OBIO 0.04
- Stochastic Oscillator
- CGEN 85.32
- OBIO 74.45
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.